CHMP backs Joenja for APDS, moving Pharming closer to EU approval

Pharming has cleared an important European regulatory hurdle for Joenja (leniolisib), with CHMP issuing a positive opinion for use in activated phosphoinositide 3-kinase delta syndrome in adults and children ages 12 and older. The March 27, 2026, opinion puts the oral PI3Kδ inhibitor one step from European Commission authorization and, if approved, would make it the first authorized APDS treatment in the EU. (stocktitan.net)

The decision also closes the loop on a review that had been delayed for nearly two years. In May 2024, Pharming disclosed that CHMP’s remaining concern was not clinical efficacy, but a chemistry, manufacturing, and controls issue tied to regulatory starting materials in the manufacturing process. At that point, the company said CHMP had already concluded the clinical benefit of leniolisib was positive, but required the manufacturing work to be completed before approval, extending the review timeline to January 2026. (pharming.com)

The evidence package behind the filing has been consistent throughout that process. Pharming’s application was based on a multinational, triple-blind, placebo-controlled, randomized Phase II/III trial in 31 patients with APDS ages 12 and older, which met its co-primary endpoints, along with open-label extension data from 37 patients treated for a median of three years. In company materials tied to the CHMP opinion, Pharming said the studies showed statistically significant improvement in immune dysregulation and immunodeficiency markers. (pharming.com)

The broader regulatory backdrop has shifted in Pharming’s favor. Joenja was first approved in the U.S. in March 2023 for APDS in patients 12 and older, and NICE issued positive final guidance in April 2025 recommending reimbursement and use in the NHS in England and Wales for the same age group. Pharming has also been pursuing a pediatric expansion in younger children ages 4 to 11, though that path hit a setback in the U.S. when the company disclosed a Complete Response Letter in February 2026 after an FDA priority review. Separately, company-linked coverage says Japan approved Joenja in March 2026, including for patients as young as 4. (pharming.com)

Direct outside expert reaction to the CHMP opinion was limited in the immediate coverage we could find, but Pharming has consistently framed APDS as an underdiagnosed, progressive primary immunodeficiency with a meaningful diagnostic delay, and prior company materials cite a median delay of seven years before diagnosis. That framing helps explain why regulators and health technology assessors have treated leniolisib as addressing a high unmet need in a very small, genetically defined population. (globenewswire.com)

Why it matters: For veterinary professionals, this is less about immediate clinical crossover than about the direction of travel in immunology and rare disease care. APDS is a human primary immunodeficiency, but Joenja’s progress underscores how targeted, mechanism-based therapies are increasingly being developed for narrowly defined immune dysregulation disorders. That trend can influence comparative immunology research, expectations for molecular diagnostics, and the way specialty medicine talks about pathway-driven disease. It’s also a reminder that regulatory outcomes can hinge as much on manufacturing readiness as on efficacy, a useful lesson for anyone tracking translational therapeutics from bench to clinic. (pharming.com)

There’s also a business signal here. Pharming reported strong 2025 growth driven in part by Joenja uptake, and earlier this month said it expected a CHMP opinion in the first half of 2026 with possible European Commission approval in the same period. A positive EU decision would expand access across the bloc and could strengthen the company’s rare disease platform even as it works through the pediatric U.S. setback and continues development in other immune dysregulation indications. (globenewswire.com)

What to watch: The key near-term milestone is the European Commission’s final decision, which typically follows a positive CHMP opinion by about two months, with Pharming guiding to Q2 2026. Beyond that, watch whether EU authorization changes diagnosis and referral patterns for APDS, and whether Pharming can regain momentum in younger pediatric patients after the February 1, 2026, FDA Complete Response Letter. (stocktitan.net)